Clasp Therapeutics

Biotech · Private

Selective kinase inhibitors targeting genomically defined cancers

clasptx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3320Optimeos Life Sciences, Inc.—$3.3M
3321Applied Proteomics, Inc.—$50M
3322DNA SEQ 2, INC.—$1.2M
3323Clasp Therapeutics——
3324Cgenetech, Inc.——
3325HSIRI THERAPEUTICS——
3326Grit Bio Inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Modified Mana-tces Targeting Tumor Antigens And Engaging T Cell Receptors, And Methods Of Using Thereofapplication
  • Modified Mana-tces Targeting Tumor Antigens And Engaging T-cell Receptors And Methods Of Usingapplication
  • Modified Mana-tces Targeting Tumor Antigens And Engaging T Cell Receptors, And Methods Of Using Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.